LOGIN
Osteosarcoma: methotrexate & doxorubicin versus methotrexate, etoposide & ifosfamide
October 2013
Osteosarcoma: methotrexate & doxorubicin versus methotrexate, etoposide & ifosfamide
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients
Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
234 patients with nonmetastatic osteosarcoma were randomized to preoperative chemotherapy of high-dose methotrexate with either doxorubicin or with etoposide and ifosfamide. After a median of 77-month follow-up, patients who had received the etoposide-ifosfamide regimen exhibited a larger percentage of good histologic response. Three- and 5-year overall and event-free survival rates were significa...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.